Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.639548
Title: Immune reconstitution of B cell and T cell compartments following reduced intensity allogeneic stem cell transplantation for myeloma
Author: D'Sa, S. P.
Awarding Body: University of London
Current Institution: University College London (University of London)
Date of Award: 2007
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Immune reconstitution following conventional allogeneic transplantation is a major determinant of survival. A detailed investigation of T and B cell immune reconstitution and clinical outcome in 19 patients with myeloma undergoing reduced intensity stem cell transplantation using in vivo T cell-depletion with alemtuzumab was undertaken. The rate of recovery of lymphocyte numbers and function following transplant was studied using immunophenotyping with 3-colour flow cytometry and intracellular cytokine staining. In addition, T and B cell spectratyping were used to study the repertoire of immune recovery. The patients in this study experienced delayed T cell recovery and T cell receptor spectratype analysis showed a reduced repertoire diversity, which improved rapidly following the administration of DLI and subsequent conversion to full donor T cell chimerism. Post transplant recovery of B cells was also significantly delayed. Spectratype analysis of IgH CDR3 repertoire revealed a gradual normalisation in spectratype complexity by 6- 12 months post transplant. There was a high incidence of viral infection, particularly CMV reactivation but the regimen related mortality was low, perhaps due to the very low incidence of severe acute graft-versus-host disease (GVHD). A total of 10 patients experienced GVHD. Of these patients, 8 eventually demonstrated a disease response alongside clinical evidence of GVHD, demonstrating that the graft-versus-myeloma effect is frequently obtained at the expense of GVHD. Over 80% of all patients have relapsed at a median of 9 months following transplant, suggesting that the initially low rate of GVHD has been achieved at the expense of the desired graft-versus-myeloma effect.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.639548  DOI: Not available
Share: